The K drug is pabolizumab and the regimen is thirty minutes or more per infusion every three weeks until progression or intolerable adverse effects occur. The indications for this product are malignancies such as melanoma, non-small cell lung cancer, esophageal cancer, squamous cell carcinoma of the head and neck, and colorectal cancer. Adverse reactions: immune-related pneumonia, hepatitis, colitis, skin inflammation, and endocrine reactions. For patients with first-degree adverse reactions, the drug can be continued after symptomatic treatment and symptoms are relieved; for those with fourth-degree adverse reactions, the drug should be permanently discontinued. Contraindications: It is contraindicated for those who are allergic to the active ingredients and excipients of this product. In conclusion, pembrolizumab needs to be used under the guidance of a doctor, closely observe adverse reactions, regular review, and do close follow-up, do not self-medication, so as not to delay the condition.